Erratum: Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease (Neurology (2007) 68 (911-915) DOI: 10.1212/01.wnl.0000257089.50476.92);Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease

Neurology

Volumn 68, Issue 12, 2007, Pages 911-915

  Sato, Yoshihiro ^a   Honda, Yoshiaki ^a   Iwamoto, Jun ^b  

^a Mitate Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENNET; DEOXYPYRIDINOLINE; ERGOCALCIFEROL; LEVODOPA; PLACEBO; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; ESOPHAGITIS; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 34147108671     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003021     Document Type: Erratum

References (20)

1. Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH. Bone mineral density in patients with Parkinson's disease measured by dual photon absorptiometry. Nucl Med Commun 1994;15:173-177.
2. Taggart H, Crawford V. Reduced bone density of the hip in elderly patients with Parkinson's disease. Age Ageing 1995;24:326-328.
3. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997;49:1273-1278.
4. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001;82:89-93.
5. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1α-hydroxyvitamin D3 in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:64-68.
6. Sato Y, Iwamoto J, Kanoko T, Satoh K. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease. A randomized controlled trial. Mov Disord 2006;21:924-929.
7. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003;33:805-811.
8. McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-340.
9. Shiraki M, Fukunaga M, Kushida K, et al. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 2003;14:225-234.
10. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352.
11. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
13. Komar L, Nieves J, Cosman F, Rubin A, Shen V, Lindsay R. Calcium homeostasis of an elderly population upon admission to a nursing home. J Am Geriatr Soc 1993;41:1057-1064.
14. Matsumoto C, Kushida K, Yamazaki K, Imose K, Inoue T. Metacarpal bone mass in normal and osteoporotic Japanese women using computed X-ray densitometry. Calcif Tissue Int 1994;55:324-329.
15. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141.
16. Derisquebourg T, Dubois P, Devogelaer JP, et al. Automated computerized radiogrametry of the second metacarpal and its correlation with absorptiometry of the forearm and spine. Calcif Tissue Int 1994;54:461-465.
17. Sato Y, Kanoko T, Yasuda H, Satoh K, Iwamoto J. Beneficial effect of etidronate therapy in immobilized hip fracture patients. Am J Phys Med Rehabil 2004;83:298-303.
18. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001;82:89-93.
19. Hagino H, Yamamoto K, Ohshiro H, Nakamura T, Kishimoto H, Nose T. Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori Prefecture, Japan. Bone 1999;24:265-270.
20. Sato Y, Oizumi K, Kuno H, Kaji M. Effect of Immobilization upon renal synthesis of 1,25-dihydroxyvitamin D in disabled elderly stroke patients. Bone 1999;24:271-275.